iX Biopharma said on Oct, 8 2026 that it has received a listing and quotation notice from the Singapore Exchange Securities Trading Limited for the listing of up to 2,682,779 new shares on the Catalist board.
The shares will be issued to Mr. Lee Vincent Seng Yong under a debt capitalisation agreement signed on Oct, 3 2026.
The listing remains subject to the fulfilment of the agreement’s conditions and compliance with SGX listing requirements, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.